Tags

Type your tag names separated by a space and hit enter

Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
Int J Antimicrob Agents. 2006 Nov; 28(5):460-4.IJ

Abstract

Burkholderia pseudomallei is the causative agent of melioidosis. Standard therapy includes ceftazidime alone or in combination with co-trimoxazole. Tigecycline, a novel agent, has displayed activity against B. pseudomallei. We evaluated the in vivo efficacy of tigecycline using a murine model of melioidosis. Mice were infected with either a high or low virulence B. pseudomallei isolate followed by administration of antibiotics alone or in combination (tigecycline, ceftazidime, tigecycline plus ceftazidime) for 7 days. Bacterial loads were assessed up to 7 days and survival was determined up to 7 days post infection. Tigecycline in combination with ceftazidime was the most effective and conferred the lowest mortality, suggesting the use of this new agent in B. pseudomallei infection.

Authors+Show Affiliations

School of Veterinary and Biomedical Sciences, James Cook University, Townsville, Qld 4811, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17046208

Citation

Feterl, Marshall, et al. "Activity of Tigecycline in the Treatment of Acute Burkholderia Pseudomallei Infection in a Murine Model." International Journal of Antimicrobial Agents, vol. 28, no. 5, 2006, pp. 460-4.
Feterl M, Govan B, Engler C, et al. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. Int J Antimicrob Agents. 2006;28(5):460-4.
Feterl, M., Govan, B., Engler, C., Norton, R., & Ketheesan, N. (2006). Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. International Journal of Antimicrobial Agents, 28(5), 460-4.
Feterl M, et al. Activity of Tigecycline in the Treatment of Acute Burkholderia Pseudomallei Infection in a Murine Model. Int J Antimicrob Agents. 2006;28(5):460-4. PubMed PMID: 17046208.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. AU - Feterl,Marshall, AU - Govan,Brenda, AU - Engler,Cathy, AU - Norton,Robert, AU - Ketheesan,Natkunam, PY - 2006/06/05/received PY - 2006/07/19/revised PY - 2006/07/20/accepted PY - 2006/10/19/pubmed PY - 2007/1/24/medline PY - 2006/10/19/entrez SP - 460 EP - 4 JF - International journal of antimicrobial agents JO - Int. J. Antimicrob. Agents VL - 28 IS - 5 N2 - Burkholderia pseudomallei is the causative agent of melioidosis. Standard therapy includes ceftazidime alone or in combination with co-trimoxazole. Tigecycline, a novel agent, has displayed activity against B. pseudomallei. We evaluated the in vivo efficacy of tigecycline using a murine model of melioidosis. Mice were infected with either a high or low virulence B. pseudomallei isolate followed by administration of antibiotics alone or in combination (tigecycline, ceftazidime, tigecycline plus ceftazidime) for 7 days. Bacterial loads were assessed up to 7 days and survival was determined up to 7 days post infection. Tigecycline in combination with ceftazidime was the most effective and conferred the lowest mortality, suggesting the use of this new agent in B. pseudomallei infection. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/17046208/Activity_of_tigecycline_in_the_treatment_of_acute_Burkholderia_pseudomallei_infection_in_a_murine_model_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(06)00354-2 DB - PRIME DP - Unbound Medicine ER -